Lytic and latent EBV gene expression in transplant recipients with and without post-transplant lymphoproliferative disorder-Reference-Cited by-同舟云学术

Lytic and latent EBV gene expression in transplant recipients with and without post-transplant lymphoproliferative disorder

Published:2011-11 Issue:3 Volume:52 Page:231-235
ISSN:1386-6532
Container-title:Journal of Clinical Virology
language:en
Short-container-title:Journal of Clinical Virology

Author:

Kroll Jing,Li Shaobing,Levi Marilyn,Weinberg Adriana

Publisher

Elsevier BV

Subject

Infectious Diseases,Virology

Reference41 articles.

1. Marked increased risk of Epstein–Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation;Brunstein;Blood,2006

2. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation;Comoli;Am J Transplant,2007

3. Risks of developing Epstein–Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants CAMPATH Users;Hale;Blood,1998

4. A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation;Peniket;Bone Marrow Transplant,1998

5. The role of HLA mismatch, splenectomy and recipient Epstein–Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation;Sundin;Haematologica,2006

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Screening and Management of PTLD;Transplantation;2023-10-21

2. Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation;Biomedicine & Pharmacotherapy;2023-08

3. The IPTA Nashville Consensus Conference on Post‐Transplant lymphoproliferative disorders after solid organ transplantation in children: III – Consensus guidelines for Epstein‐Barr virus load and other biomarker monitoring;Pediatric Transplantation;2023-06-09

4. Post-Transplant Lymphoproliferative Disorders;Pediatric Solid Organ Transplantation;2023

5. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein–Barr virus–associated post-transplant lymphoproliferative disorder;Kidney International;2022-12